Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Achieving and maintaining a high-quality response is the treatment goal for patients with
newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in …

Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …

Purpose To investigate the prognostic value of minimal residual disease (MRD) assessment
in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma …

Patients with multiple myeloma (MM) carrying standard-or high-risk cytogenetic
abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior …

Background Extramedullary disease is an uncommon manifestation in multiple myeloma
and can either accompany newly diagnosed disease or develop with disease progression or …

Minimal residual disease (MRD) assessment is incorporated in an increasing number of
multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a …